Skip to main content

INDIA MAY DRAG USA TO WTO

India will drag the US to the WTO if Washington decides to put New Delhi in the Priority Foreign Country list for intellectual property rights (IPR), which could lead to trade curbs on domestic firms, sources said. This was decided at a high-level meeting called by Cabinet Secretary Ajit Seth to discuss problems related to IPR issues with the US, especially in the pharmaceutical sector. "Indian IPR laws are fully compliant with WTO and other international norms. Any unilateral action taken by the US will be violative of WTO and India will suitably respond by dragging the US to WTO's dispute resolution mechanism," sources told PTI. US industry, particularly the pharmaceuticals sector, and trade lobbies have been putting pressure on their government to place India under the Priority Foreign Country list for IPR. Under the US Trade Act, a Priority Foreign Country is the worst classification given to those that deny adequate and effective protection of IPR or fair and equitable market access to US entities relying on IPR protection. The US Trade Representative is scheduled to come out with a report on April 30 on Special 301, which also talks about the priority foreign country list. "We are waiting for that report. The Indian government will not engage with private American firms," they added. Indian Ambassador to US S Jaishankar had suggested that the government should engage with US pharma firms on the matter. US companies allege India's IPR regime is not compliant with international norms and discriminates against them. Officials at the meeting, including Foreign Secretary Sujatha Singh, Commerce Secretary Rajeev Kher, DIPP Secretary Amitabh Kant and Health Secretary Lov Kumar Verma, appraised the Cabinet Secretary on all IPR-related issues between India and the US. According to sources, as part of trade sanctions, the US may consider withdrawing benefits under the scheme of Generalised System of Preferences (GSP), which provides reduced tariffs for Indian goods entering the US markets. "The withdrawal of GSP benefits may impact exports of MSME sector to the US. However, overall, the move would not impact Indian exporters much," they said. Officials have said the demand is completely unfair as India's IPR regime is compliant with global laws, including the World Trade Organisation (WTO).
The Obama administration has strongly criticised India's investment climate and IPR laws, especially in the pharmaceutical and solar sectors. US pharma companies had objected to India's move in March 2012 to allow Hyderabad-based Natco Pharma to manufacture and sell a generic copy of cancer-treatment drug Nexavar at about 3 per cent of the cost charged by patent holder Bayer. India's pharma exports increased 10 per cent to USD 14.6 billion during 2012-13, with shipments to the US accounting for about 26 per cent of the total. India is the largest exporter of generic drugs to the US by volume. It has about 320 FDA-approved pharma facilities, the largest number outside the US. The US Food and Drug Administration (FDA) has taken a series of actions against some Indian pharmaceutical firms, restricting their shipments to the US, their largest export market. 

Comments

Popular posts from this blog

JIO TARIFF CICK FOR TELECOM STOCKS

Telecom stocks today surged up to 8 per cent after the recent increase in Reliance Jio tariffs, which is largely seen as positive for the sector. Shares of Bharti Airtel jumped 4.99 per cent to close at Rs 497.50 on BSE. Bharti Airtel was the biggest gainer among the 30-share index components. The scrip of Idea Cellular soared 7.74 per cent to end at Rs 98.15 and Reliance Communications zoomed 7.60 per cent to Rs 17.70. Reliance Jio made its service dearer by about 15 per cent for its popular 84-day plan at Rs 459 from October 19, under which subscribers get 1GB 4G data at high speed per day. The company restructured its various schemes by reducing their validity period. The recent increase in Reliance Jio tariffs will increase its average revenue per user by up to 20 per cent and is a positive for the telecom sector, which is seeing a rapid consolidation, says a Philip Capital report. Established telecom sector players have seen huge reduction in their margins. Idea Cellular and Reli…

STOCK MARKET WELCOME NEW YEAR WITH LOSS

Sensex drops 244 pts
A late sell-off in auto, banking and IT shares pulled back the benchmark BSE Sensex from record high level to close down by 244 points, its biggest single loss in past one month, on the first trading day of 2018. Investors preferred to book profits at record highs amid concerns over fiscal slippages and rising crude oil prices and absence of cues from global markets which were closed for the New Year holiday. The benchmark Sensex touched a low of 33,766.15 before settling lower by 244.08 points, or 0.72 per cent, at 33,812.75. This is the biggest single-day fall since December 1 when the index had lost 316.41. The 30-share index had closed at an all-time high of 34,056.83 in the last session of 2017 on Friday. Also, the 50-share Nifty cracked below the 10,500-mark to hit a low of 10,423.10 before settling 95.15 points, or 0.90 per cent down at 10,435.55. Stocks opened on a weak note and remained range-bound for the better part of the day but an intense sell-off in…

NIFTY EARNINGS FLAT IN 2018

UBS Cautious Note

Projecting zero returns from the Nifty, Swiss brokerage UBS has projected a 10 per cent cut in its index target at 10,500 for calendar 2018, even as it remains positive over the long-term. "Top-down, we forecast Nifty earnings growth will recover from 9 per cent in fiscal 2018 to 13 per cent in 2019, but driven largely by financials," the brokerage said in a report. "However, earnings growth is likely to disappoint against consensus forecast of 22 per cent growth for fiscal 2019, implying a 10 per cent cut," it added. Accordingly, the brokerage estimates "no returns from the Nifty in 2018" and has set the index target at 10,500 for this December. The report noted that a sharp earnings recovery, with continued robust macro stability appears priced in by the markets. "A sharp earnings recovery appears priced in. The markets are already close to our 2018 target, given optimistic fiscal 2019 consensus earnings expectations, which build …